Fig. 5: Effect of treatment intensification by the Burkitt protocol in patients with a positive interim PET scan. | Leukemia

Fig. 5: Effect of treatment intensification by the Burkitt protocol in patients with a positive interim PET scan.

From: Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial

Fig. 5

Overall, patients receiving treatment intensification by the Burkitt protocol did not have a statistically longer TTP than patients receiving standard R-CHOP (A). Patients with a positive interim PET scan were grouped by an optimized mean-SUVAI threshold (SUV 4.78) into those with high versus low FDG uptake (B). In patients with low mean-SUVAI, no statistically significant difference between patients treated with R-CHOP or the Burkitt protocol was observed (C). In contrast, in the high mean-SUVAI subgroup, patients treated with R-CHOP had statistically significantly longer TTP than those treated with the Burkitt protocol (D). For comparison, the conventional metrics max-SUVmanual (E) and decline in SUVmax between baseline and interim PET (F) could also identify patients who showed longer TTP in response to treatment with R-CHOP over the Burkitt protocol.

Back to article page